Country: Canada
Language: English
Source: Health Canada
CISATRACURIUM (CISATRACURIUM BESYLATE)
OMEGA LABORATORIES LIMITED
M03AC11
CISATRACURIUM
2MG
SOLUTION
CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG
INTRAVENOUS
10*5ML
Prescription
NEUROMUSCULAR BLOCKING AGENTS
Active ingredient group (AIG) number: 0133260001; AHFS:
APPROVED
2013-06-28
PRODUCT MONOGRAPH PR C ISATRACURIUM O MEGA S INGLE D OSE Cisatracurium Besylate Injection 2 mg/mL cisatracurium (5 mL single dose vial) PR C ISATRACURIUM O MEGA M ULTI -D OSE Cisatracurium Besylate Injection 2 mg/mL cisatracurium (10 mL multiple dose vial) NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT Sterile solution THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED PROFESSIONALS FAMILIAR WITH ITS ACTIONS, CHARACTERISTICS, AND HAZARDS. Omega Laboratories Limited 11 177, Hamon Montreal, Canada H3M 3E4 DATE OF PREPARATION : June 27, 2013 SUBMISSION CONTROL NO: 138615 Page 2 of 37 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................. 3 SUMMARY PRODUCT INFORMATION.................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................... 3 CONTRAINDICATIONS ............................................................................................... 4 WARNINGS AND PRECAUTIONS ............................................................................. 4 ADVERSE REACTIONS ............................................................................................. 10 DRUG INTERACTIONS ............................................................................................. 11 DOSAGE AND ADMINISTRATION ......................................................................... 13 OVERDOSAGE ............................................................................................................ 19 ACTION AND CLINICAL PHARMACOLOGY ........................................................ 20 STORAGE AND STABILITY ..................................................................................... 27 SPECIAL HANDLING INSTRUCTIONS ................................................................... 28 DOSAGE FORMS, COMPOSITION AND PACKAGING ......................................... 28 PART II: SCIENTIFIC INFORMATION ................................... Read the complete document